Clinical Trials Browser

Phase 2 × NETWORK × Imatinib Mesylate × Clear all

NCT03516279 2026-03-02

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase, Neoplasm, Residual

NCT03654768 2025-12-18

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

Phase 2 Active not recruiting

81 enrolled 20 charts

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

NCT00928525 2023-10-05

Basket 1

Phase 2 Completed

Advanced Desmoid Tumor

NCT02365441 2023-07-07

ALT GIST

Phase 2 Unknown

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT04578847 2020-10-08

READIT

Phase 2 Unknown

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00085475 2012-09-24

Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma

Phase 2 Completed

Fibrosarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

NCT00039364 2012-07-24

Imatinib Mesylate in Treating Patients With Gliomas

Phase 2 Completed

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Glioma, Subependymal, Gliosarcoma